Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.65 |
| ▸ | LSS | P48449 | 1/20 | 0.62 |
| ▸ | PDE1A | P54750 | 7/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 7/20 | 0.61 |
| ▸ | PDE1C | Q14123 | 7/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645547 | 0.90 | HRH3 (0.63) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL9671156 | 0.89 | KDM4E (0.83) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL12230255 | 0.88 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL9440426 | 0.82 | LTA4H (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3PDE1A | |
| SCHEMBL8226392 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL16314649 | 0.80 | FDPS (0.48) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL15978587 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL3444779 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL6784753 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HRH3LSS | |
| SCHEMBL12110236 | 0.80 | KDM4E (0.69) | KDM4EALDH1A1SMN1; SMN2HRH3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730717-B1 | Melanin-inspired antimicrobial | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730717-B1 | Melanin-inspired antimicrobial | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730717-B1 | Melanin-inspired antimicrobial | The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges (US) | 2023-08-22 | — | — | US | disclosed |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2020-12-29 | — | — | US | disclosed |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIV FLORIDA (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIV FLORIDA (US) | 2017-06-15 | — | — | US | disclosed |
| US-9549549-B2 | Antimicrobial materials and methods | STC.UNM (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549549-B2 | Antimicrobial materials and methods | STC.UNM (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160031910-A1 | LANTHANIDE COMPLEXES COMPRISING AT LEAST TWO BETAINE GROUPS, WHICH CAN BE USED AS LUMINESCENT MARKERS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2016-02-04 | — | — | US | disclosed |
| US-20160031910-A1 | LANTHANIDE COMPLEXES COMPRISING AT LEAST TWO BETAINE GROUPS, WHICH CAN BE USED AS LUMINESCENT MARKERS | ECOLE NORMALE SUPERIEURE DE LYON (FR) | 2016-02-04 | — | — | US | disclosed |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128535-A1 | Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof | CHEK2, CHEK1, ATM | KDM4E 1694/4885ALDH1A1 1975/4885SMN1; SMN2 2929/4885 |
| US-11730717-B1 | Melanin-inspired antimicrobial | TYR, MCHR1, EEA1 | KDM4E 192/4885ALDH1A1 2565/4885SMN1; SMN2 4555/4885 |
| US-10874670-B2 | Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof | CHEK1, CHEK2, CDK1 | KDM4E 372/4885ALDH1A1 1876/4885SMN1; SMN2 3616/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | KDM4E 2751/4885ALDH1A1 716/4885SMN1; SMN2 4137/4885 |
| US-20160031910-A1 | LANTHANIDE COMPLEXES COMPRISING AT LEAST TWO BETAINE GROUPS, WHICH CAN BE USED AS LUMINESCENT MARKERS | SLC6A12, LGALS3, LBR | KDM4E 3365/4885ALDH1A1 1624/4885SMN1; SMN2 4399/4885 |
| US-11547703-B2 | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | CHEK2, CHEK1, ATM | KDM4E 1694/4885ALDH1A1 1975/4885SMN1; SMN2 2929/4885 |
| US-20170164614-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | KDM4E 2673/4885ALDH1A1 2629/4885SMN1; SMN2 4458/4885 |
| US-20140242148-A1 | ANTIMICROBIAL MATERIALS AND METHODS | AOC3, OGFOD1, DDT | KDM4E 2673/4885ALDH1A1 2629/4885SMN1; SMN2 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.